S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,733.80 +1.31%

S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,733.80 +1.31%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

DBVT

DBV Technologies S.A. NCM · DBVT

$14.70 -0.16 (-1.08%)

Pullback · -1.37σ

+ Compare Open in Sniper

News · DBVT

Full news feed →

DBV Technologies dépose un prospectus relatif à son Programme At-The-Market (ATM) pour un montant pouvant atteindre 150 millions de dollars

GlobeNewswire Inc. · 1d ago

DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing

GlobeNewswire Inc. · 19d ago

DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference

GlobeNewswire Inc. · 39d ago

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

GlobeNewswire Inc. · 40d ago

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

GlobeNewswire Inc. · 45d ago

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

GlobeNewswire Inc. · 96d ago

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

GlobeNewswire Inc. · 107d ago

DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting

GlobeNewswire Inc. · 140d ago

DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing

GlobeNewswire Inc. · 182d ago

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

GlobeNewswire Inc. · 192d ago

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

Benzinga · 199d ago

DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

GlobeNewswire Inc. · 248d ago

Food Allergy Market Valued at USD 3 Billion across the 7MM, Projected to Grow at CAGR of 11.3% by 2034 | DelveInsight

GlobeNewswire Inc. · 250d ago

DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq

GlobeNewswire Inc. · 261d ago

DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq

GlobeNewswire Inc. · 261d ago

DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document

GlobeNewswire Inc. · 463d ago

DBV Technologies Announces Plan to Implement ADS Ratio Change

GlobeNewswire Inc. · 614d ago